ERBB2 and breast carcinoma: Against breast cancer, FIS exhibited cytotoxicity against most breast cancer subtypes including triple negative breast cancer (TNBC) [6] in addition to estrogen receptor and human epidermal growth factor receptor 2-overexpressing breast cancer cell [7].